Colloidal bismuth subcitrate (De-Nol) inhibits degradation of gastric mucus by Campylobacter pylori protease
- PMID: 2470250
Colloidal bismuth subcitrate (De-Nol) inhibits degradation of gastric mucus by Campylobacter pylori protease
Abstract
There is increased awareness that infection with Campylobacter pylori could be a major factor in the pathogenesis of gastric disease. Here, we present evidence that the extracellular protease elaborated by this bacteria, which causes degradation of gastric mucus, is inhibited by an antiulcer agent, colloidal bismuth subcitrate (CBS; De-Nol). The study was conducted with C. pylori cultured from antral mucosal biopsy specimens of patients undergoing gastroscopy. The grown colonies of bacteria were washed with saline, filtered through sterilization filter, dialyzed, and lyophilized. The powder was used as the enzyme source for proteolytic activity assay employing pig gastric mucus as substrate. Optimum enzymatic activity was obtained at 37 degrees C and at pH 7.0. The apparent Km of C. pylori protease with gastric mucus was 0.71 g/L. Analyses of the degradation products indicated that the protease caused extensive proteolysis of mucus glycoprotein polymer. Introduction of CBS to the incubation mixtures led to a reduction of the rate of mucus degradation. The rate of proteolysis inhibition was proportional to CBS concentration up to 1 X 10(-1) g/L, at which point a 37% reduction in mucus proteolysis was obtained. The Km value for proteolytic degradation of mucus by C. pylori protease in the presence of CBS was 1.25 g/L. The results suggest that CBS is capable of counter-acting the proteolysis of the protective gastric mucus layer by C. pylori.
Similar articles
-
Colloidal bismuth subcitrate inhibits peptic degradation of gastric mucus and epidermal growth factor in vitro.Am J Gastroenterol. 1990 Apr;85(4):390-3. Am J Gastroenterol. 1990. PMID: 2109526
-
Lipolytic activity of Campylobacter pylori: effect of colloidal bismuth subcitrate (De-Nol).Am J Gastroenterol. 1989 Oct;84(10):1273-7. Am J Gastroenterol. 1989. PMID: 2801678
-
Treatment of Campylobacter pylori gastritis: a pilot study using pirenzepine dihydrochloride (Gastrozepin) and three formulations of colloidal bismuth subcitrate (De-Nol).N Z Med J. 1988 Oct 26;101(856 Pt 1):651-4. N Z Med J. 1988. PMID: 3054641 Clinical Trial.
-
Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.Drugs. 1988 Aug;36(2):132-57. doi: 10.2165/00003495-198836020-00002. Drugs. 1988. PMID: 3053124 Review.
-
The mode of action of colloidal bismuth subcitrate.Scand J Gastroenterol Suppl. 1991;185:1-6. doi: 10.3109/00365529109093213. Scand J Gastroenterol Suppl. 1991. PMID: 1957120 Review.
Cited by
-
Helicobacter pylori: a Jordanian study.Postgrad Med J. 1991 Nov;67(793):994-8. doi: 10.1136/pgmj.67.793.994. Postgrad Med J. 1991. PMID: 1775426 Free PMC article.
-
Peptic ulcer surgery in patients with liver cirrhosis.Ann Surg. 1993 Apr;217(4):338-46. doi: 10.1097/00000658-199304000-00005. Ann Surg. 1993. PMID: 8466308 Free PMC article.
-
Effect of Helicobacter pylori infection on colloidal bismuth subcitrate concentration in gastric mucus.Gut. 1992 May;33(5):592-6. doi: 10.1136/gut.33.5.592. Gut. 1992. PMID: 1377152 Free PMC article.
-
Gastric mucosal barrier: evidence for Helicobacter pylori ingesting gastric surfactant and deriving protection from it.Gut. 1993 May;34(5):588-93. doi: 10.1136/gut.34.5.588. Gut. 1993. PMID: 8504956 Free PMC article.
-
Growth in and breakdown of purified rabbit small intestinal mucin by Yersinia enterocolitica.Infect Immun. 1993 Oct;61(10):4131-8. doi: 10.1128/iai.61.10.4131-4138.1993. Infect Immun. 1993. PMID: 8406802 Free PMC article.